Overview

• Post By :


• Source: Microbioz India


• Date: 22 Jun,2026

Sun Pharmaceutical Industries, India’s biggest pharmaceutical drug maker, is buying 100% Mumbai-based Innovcare Lifesciences for an all-cash transaction worth $28.7 million. The transaction is expected to close on or before July 31, 2026.

Sun Pharma Expands Indian Healthcare Portfolio with ₹271 Crore Innovcare Lifesciences Acquisition

This acquisition will allow Sun Pharma to continue on its path to strengthening its formulations and to growing its presence in therapeutics that are high on demand. Innovcare Lifesciences is operating in India in the marketing, distribution, and sales of drugs, nutraceuticals, and cosmeceuticals.

Sun Pharma have stated that this acquisition is going to expand their offerings and increase their presence in the growing Indian healthcare market and will allow them to solidify their leadership in the specialty and branded healthcare segments.

Innovcare, which was established in 2014 and only operates in India, recorded operational revenues of nearly ₹94.06 Crore in FY2026, which is an increase from ₹86.09 Crore in FY2025. This shows that there has been an increase in the business and greater acceptance of their products in the market.

Sun Pharma added that this acquisition is not a related party transaction as Innovcare has no promoters or stake holders from the Sun Pharma Group. The acquisition will be fully cash funded and will be a fast transaction as there are no major approvals needed.

This acquisition occurs as Sun Pharma focuses on several avenues for growth including expansion of its global footprint. Experts think that acquisitions like Innovcare will allow the company to diversify their portfolio, strengthen engagement with physicians, and grow with the Indian market’s versatile, chronic care, wellness, and preventive health demand.